OliX Pharmaceuticals (226950) Fundamentals 2026 — Revenue Analysis | SniperIQ
OliX Pharmaceuticals (226950) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩2.09T, trading at ₩103000.00 on the KOE. This SniperIQ fundamentals page covers OliX Pharmaceuticals's valuation, profitability (net margin -70.9%), revenue (₩14.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is OliX Pharmaceuticals's market cap?
OliX Pharmaceuticals (226950) has a market capitalization of approximately ₩2.09T, trading at ₩103000.00 on the KOE. Market cap moves with the live share price.
What is OliX Pharmaceuticals's P/E ratio?
OliX Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 15.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is OliX Pharmaceuticals?
OliX Pharmaceuticals runs a net profit margin of -70.9%, a gross margin of 93.3%, and an operating margin of -188.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does OliX Pharmaceuticals generate?
OliX Pharmaceuticals reported revenue of ₩14.7B for fiscal year 2025, with net income of -₩16.2B and earnings per share (EPS) of -804. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does OliX Pharmaceuticals pay a dividend?
OliX Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is OliX Pharmaceuticals financially healthy?
OliX Pharmaceuticals carries a debt-to-equity ratio of 0.15x and a current ratio of 6.59x, with a market beta of 0.23. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is OliX Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For OliX Pharmaceuticals (226950) the key facts are: market cap ₩2.09T, revenue ₩14.7B, 52-week range 42600-217000. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track OliX Pharmaceuticals's full fundamentals live
Get OliX Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.